Figure 2

vIF2α inhibits human PKR-mediated toxicity in yeast. Plasmids expressing VACV K3L (pC140) or RCV-Z vIF2α (pC3853) under the control of a yeast GAL-CYC1 hybrid promoter, or the vector pEMBLyex4 alone, were introduced into isogenic yeast strains having either an empty vector (A, control, J673) or a GAL-CYC1-human PKR construct (B, J983) integrated at the LEU2 locus. The indicated transformants were streaked on SC-Gal medium where expression of both PKR and the viral proteins was induced, and incubated at 30°C for 4 days. Results shown are representative of 4 independent transformants for each plasmid.